Aesica and The University of Nottingham Collaborate
News May 08, 2013
Amide bond formation is fundamental part of pharmaceutical manufacturing, and is utilised in 84% of a set of drug candidates.
The partnership's aim is to revolutionise traditional amide formation techniques by generating alternative, eco-friendly and chemically versatile methods for amide bond formation.
According to the company, the approach will be commercially available in the next two to three months and the company is already actively seeking commercial opportunities to work with potential compounds that could benefit from this novel technology.
Aesica envisages this new development will lower production costs whilst offering the potential of higher chemical yields.
University of Nottingham Synthetic Organic Chemistry professor Simon Woodward said that one of the departments goals has been to see this novel technology used in larger scale industrial environments.
"We look forward to collaborating with Aesica and seeing the full commercial potential of this novel technology in API manufacture," said Woodward.
Aesica Pharmaceuticals Technology Development director Barrie Rhodes said that the new amide production technology will enable cheaper and simpler routes to market for many compounds.
"Professor Woodward's ability to carry out high calibre research coupled with our desire to bring new economically important and innovative technologies to the market is the basis for a truly collaborative partnership," Rhodes said.
BIA Separations appoints Pete Gagnon as Chief Scientific OfficerNews
Appointment will drive new product and applications development.READ MORE
PPD and Quotient Sciences Form Innovative Partnership to Accelerate Pediatric Drug DevelopmentNews
Will shorten timelines, reduce costs and simplify contracting process in pediatric programs.READ MORE
Batavia Biosciences Teams Up with International Consortium to Support Polio EradicationNews
Batavia Biosciences announces its partnership with an international consortium coordinated by PATH aiming to develop and manufacture safer novel oral poliovirus vaccines (nOPV).READ MORE